The effect of Autologous Platelet-Rich Plasma (PRP) on ovarian functio

Phase 2

• Conditions: Condition 1: Premature ovarian failure. Condition 2: Poor ovarian responders.; Female infertility associated with anovulation; N97.0

• Registration Number: IRCT20180818040828N2
• Lead Sponsor: Yazd University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 30

Inclusion Criteria

Patient with premature ovarian failure
patient with poor ovarian reserve (AFC<5-7 and AMH<0.5-1.1 ng/ml)

Exclusion Criteria

IgA deficiency
Ovarian failure secondary to sex chromosome abnormality
Pelvic adhesion scondary to abdominal surgery
Chronic pelvic pain

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
FSH level. Timepoint: Some days before injection and 1, 2 months after injection. Method of measurement: Check in labratory.;AMH level. Timepoint: Some days before injection and 1, 2 months after injection. Method of measurement: Check in labratory.;Estradiol level. Timepoint: Some days before injection and 1, 2 months after injection. Method of measurement: Check in labratory.;LH level. Timepoint: Some days before injection and 1, 2 months after injection. Method of measurement: Check in labratory.

Secondary Outcome Measures

Name	Time	Method
Chemical pregnancy. Timepoint: 1 year after the first PRP injection. Method of measurement: Laboratory measurement of Beta hCG.;Clinical pregnancy. Timepoint: 5 weeks after positive Beta hCG. Method of measurement: Observation of fetal heart rate in sonography.;Live birth. Timepoint: 36 weeks after positive Beta hCG. Method of measurement: Delivery of live-born baby.